摘要
目的:探讨血浆B型利钠肽(BNP)与慢性心力衰竭(CHF)的关系。方法:对48例CHF患者和10名正常 人,以固相免疫分析法(IRMA)测定血浆BNP,其中33例心功能稳定于NYHAⅡ-Ⅲ级的CHF患者分为2组,随 访3个月。A组(n=12):应用地高辛、利尿剂和ACEI治疗;B组(n=21):在上述治疗的基础上,加用卡维地洛。 比较两组血浆BNP水平,及心脏彩超检查的心脏结构和功能变化。结果:(1)CHF患者血浆BNP水平显著升高,严 重心衰患者更明显(P均<0．05);(2)两组治疗后血浆BNP水平均较治疗前显著降低(P<0．05);(3)治疗后心功 能改善者血浆BNP水平下降较未改善者更明显(P<0．05);(4)B组心功能改善较A组更明显(P<0．05)。结论: CHF患者血浆BNP水平升高,其水平随心衰加重而升高。
Objective： To assess the clinical signification of plasma BNP in patients with chronic heart failure （CHF）. Methods： A total of 48 CHF patients and 10 normal controls were enrolled. The 33 CHF patients were divided into two groups and followed up for 3 month. Group A： using digoxin, diuretics and ACEI. Group B： upon those therapy the β- blockers added. The plasma BNP was measured by Immunoradiometric assay. Results ： The plasma levels of BNP significantly increased in CHF patients compared with controls and related to the severity of heart failure （P〈 0. 05 all）. Plasma BNP significantly reduced after therapy （P〈0.05）. Conclusion： BNP level significantly increase in CHF patients and related to the severity of heart failure, may regard as index for evaluating heart function .
出处
《心血管康复医学杂志》
CAS
2005年第6期527-529,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
利钠肽
B型
心力衰竭
充血性
卡维地洛
Natriureticpeptide. type B
Heart failure, congestive
Karvedilol
